- Home
- COEP vs GNTA Comparison
COEP vs GNTA Comparison
Compare COEP & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COEP | GNTA |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | Italy |
| Employees | 7 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.7M | 34.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | COEP | GNTA |
|---|---|---|
| Price | $11.72 | $0.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 32.8K | ★ 53.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.32 | $0.71 |
| 52 Week High | $21.41 | $10.00 |
Technical Indicators
Market Signals| Indicator | COEP | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 45.69 | 39.45 |
| Support Level | $10.98 | $0.71 |
| Resistance Level | $13.23 | $1.70 |
| Average True Range (ATR) | 0.94 | 0.08 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 41.06 | 17.75 |
Price Performance
Historical ComparisonAbout COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.